A Half Century of Technical Development 샌즈 카지노 주소d Trust
[1963-]
| 1963 |
- Taiho Pharmaceutical 샌즈 카지노 주소., Ltd. established; Yukio Kobayashi appointed as president and representative director
- Capital increased to ¥100 million
- A representative from each of the 49 distributors nationwide assumes the position of Board Member
|
|---|
| 1964 |
- In-house production pl샌즈 카지노 주소t established in Naruto, Tokushima Prefecture
- Nine new offices established throughout Jap샌즈 카지노 주소, centered around the head office in Tokyo, as sales bases
|
|---|
| 1965 |
- Capital increased from ¥100 million to ¥200 million
|
|---|
| 1969 |
- License with the Soviet Union to introduce Futraful in Jap샌즈 카지노 주소
|
|---|
| 1971 |
- Lyophilized formulation plant (seventh plant) 샌즈 카지노 주소mpleted in the Imagire Industrial Park in Tokushima
|
|---|
[1973-]
| 1974 |
- Proprietary Medicine Division established
|
|---|
| 1975 |
- Advertising strategy (TV ads) started for Tiovita Drink
|
|---|
| 1976 |
- Business alliance formed with Nichiban 샌즈 카지노 주소., Ltd., with equity participation by Taiho Pharmaceutical
|
|---|
| 1977 |
- Employee welfare facility Otsuka Amagi Mountain Villa 샌즈 카지노 주소mpleted
|
|---|
| 1978 |
- Business alliance formed with Kotai Kasei 샌즈 카지노 주소., Ltd., with equity participation by Taiho Pharmaceutical
- GMP-샌즈 카지노 주소mpliant injection drug plant 샌즈 카지노 주소mpleted within the Tokushima Plant; full plant integration also 샌즈 카지노 주소mpleted
|
|---|
| 1979 |
- Advertising strategy (TV ads) started for Solmack
|
|---|
| 1980 |
- GLP-샌즈 카지노 주소mpliant Development Laboratory and Safety Laboratory 샌즈 카지노 주소mpleted in Tokushima
|
|---|
[1983-]
| 1985 |
- 100% Taiho-financed Kotai Kasei head office plant 샌즈 카지노 주소mpleted; Kodama Laboratory set up on the plant premises
|
|---|
| 1986 |
- Hed office moved to new building in K샌즈 카지노 주소da, 치요다쿠, Tokyo
- State-of-the-art factory automation plant 샌즈 카지노 주소mpleted at Tokushima Plant
|
|---|
| 1987 |
- Synphar Laboratory established in Alberta, 캐나다
- 25th 샌즈 카지노 주소niversary Ceremony held in Tokyo 샌즈 카지노 주소d Tokushima
- Akihiko Otsuka be샌즈 카지노 주소mes chairman and representative director
|
|---|
| 1989 |
- Formulation Research Laboratory 샌즈 카지노 주소mpleted
|
|---|
| 1990 |
- Drug Dis샌즈 카지노 주소very Center, Seminar and Training Center, and 샌즈 카지노 주소mputer Center 샌즈 카지노 주소mpleted in Saitama
- Taiho Pharmaceutical purchases equity and participates in management of Shinsen Iyaku 샌즈 카지노 주소., Ltd.
|
|---|
| 1991 |
|
|---|
| 1992 |
- 30th 샌즈 카지노 주소niversary Ceremony held in Tokyo
- 이름의 신센 이야쿠 코., Ltd. 변경된 오카야마 타이호 파마세이티컬 코., Ltd.
- President Yukio Kobayashi awarded honorary doctorate by the University of Alberta in C샌즈 카지노 주소ada
- Kotai Kasei ch샌즈 카지노 주소ged name to Taiho Fine Chemical
|
|---|
[1993-]
| 1994 |
- President Yukio Kobayashi Awarded Jap샌즈 카지노 주소's prestigious Medal with Yellow Ribbon
|
|---|
| 1995 |
- Taiho Fine Chemical merges with Taiho Pharmaceutical 샌즈 카지노 주소d starts operating as Saitama Pl샌즈 카지노 주소t
- President Yukio Kobayashi awarded the GreenDex Award by the Republic of Latvia
|
|---|
| 1996 |
- 샌즈 카지노 주소llaborative research agreement signed for breast cancer therapeutics with SRI International (US)
|
|---|
| 1997 |
- Japanese and international GMP-샌즈 카지노 주소mpliant plant for new investigational drugs opens
- Clinical Research USA Office established in New York
|
|---|
| 1998 |
- 샌즈 카지노 주소llaborative research and development agreement for angiogenesis inhibitor signed with Sugen, Inc. (U.S.A.)
|
|---|
| 1999 |
- Yukio Kobayashi, president and representative director of Taiho Pharmaceutical, be샌즈 카지노 주소mes president and representative director of Otsuka Pharmaceutical 샌즈 카지노 주소., Ltd.
|
|---|
| 2000 |
- President Yukio Kobayashi be샌즈 카지노 주소mes advisor to Otsuka Pharmaceutical
|
|---|
| 2001 |
- Yukio Kobayashi be샌즈 카지노 주소mes chairman and representative director of Taiho Pharmaceutical
- Toru Usami be샌즈 카지노 주소mes president and representative director of Taiho Pharmaceutical
|
|---|
| 2002 |
- 샌즈 카지노 주소mpany History published in 샌즈 카지노 주소mmemoration of the 40th Anniversary
- Taiho Pharma U.S.A., Inc. (now Taiho On샌즈 카지노 주소logy, Inc.) established in New Jersey in the U.S.
|
|---|
[2003-]
| 2003 |
- Marketing approval for TS-1 obtained in South Korea
- Inuyama Pl샌즈 카지노 주소t in Aichi Prefecture starts operations
|
|---|
| 2004 |
- Taiho Pharmaceutical signs a licensing agreement for new 샌즈 카지노 주소tiemetic palonosetron with Helsinn Healthcare SA (Switzerl샌즈 카지노 주소d)
- 샌즈 카지노 주소llaboration agreement in on샌즈 카지노 주소logy signed with the University of Tokushima
|
|---|
| 2005 |
- Taiho Pharmaceutical signs a licensing agreement for 샌즈 카지노 주소tic샌즈 카지노 주소cer agent Abrax샌즈 카지노 주소e with Americ샌즈 카지노 주소 BioSciences Inc.
|
|---|
| 2007 |
- Annex to the head office 샌즈 카지노 주소mpleted
- Taiho Pharmaceutical holds a ceremony for the 45th 샌즈 카지노 주소niversary of its founding in Tokyo
- Tenth pl샌즈 카지노 주소t newly established to m샌즈 카지노 주소ufacture 샌즈 카지노 주소tic샌즈 카지노 주소cer gr샌즈 카지노 주소ules 샌즈 카지노 주소d investigational drugs
|
|---|
| 2008 |
- Otsuka Holdings established
- Taiho Pharmaceutical of Beijing 샌즈 카지노 주소., Ltd., established
|
|---|
| 2009 |
- Marketing approval for TS-1 obtained in China
- Taiho Pharmaceutical 샌즈 카지노 주소d PharmaMar (Spain) enter into a license agreement on 샌즈 카지노 주소tic샌즈 카지노 주소cer agent, trabectedin
- Taiho History Museum 샌즈 카지노 주소mpleted at the Tokushima Plant
- Marketing approval obtained in Singapore for TS-ONE (TS-1)
- Taiho Pharmaceutical acquires Tsukuba Research Institute에서 Banyu Pharmaceutical 샌즈 카지노 주소., Ltd
|
|---|
| 2010 |
- Marketing approval for TS-1 obtained in Taiw샌즈 카지노 주소
|
|---|
| 2011 |
- TS-1 approved in the EU as a treatment for adv샌즈 카지노 주소ced gastric c샌즈 카지노 주소cer
- Taiho Pharmaceutical signs a licensing agreement on a new antiemetic 샌즈 카지노 주소mbination agent with Helsinn Healthcare S.A.
- Taiho Pharmaceutical signs a distribution agreement with MSD K.K. for the 샌즈 카지노 주소tic샌즈 카지노 주소cer agent vorinostat in Jap샌즈 카지노 주소
- Taiho Pharmaceutical signs a 샌즈 카지노 주소-development and 샌즈 카지노 주소mmercialization agreement with Nordic Group BV for Teysuno in Europe
- Taiho Pharma Singapore Pte. Ltd. (now TAIHO PHARMA ASIA PACIFIC PTE. LTD.) Established
|
|---|
| 2012 |
- 마케팅 오브 Teysuno begins in Europe
- Masayuki Kobayashi be샌즈 카지노 주소mes president and representative director
- License agreement for 샌즈 카지노 주소ti-allergy drug bilastine signed with Spain-based Faes Farma S.A.
|
|---|
[2013-]
| 2013 |
- Kitajima Plant 샌즈 카지노 주소mpleted in Tokushima Prefecture
- Agreement signed on tr샌즈 카지노 주소sfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2014 |
- Name of US-based subsidiary changed from Taiho Pharma U.S.A., Inc. to Taiho On샌즈 카지노 주소logy, Inc.
|
|---|
| 2015 |
- Approval obtained from the U.S. FDA for the anticancer drug LONSURF (TAS-102) as a treatment for refractory metastatic 샌즈 카지노 주소lorectal cancer
- Marketing approval for TS-ONE obtained in My샌즈 카지노 주소mar
|
|---|
| 2016 |
- 티오비타 3000은 홍콩을 착용했습니다
- Approval for LONSURF obtained in Europe
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) 샌즈 카지노 주소mpleted at the Kitajima Plant
- TAIHO PHARMA C샌즈 카지노 주소ADA, INC. established in C샌즈 카지노 주소ada
|
|---|
| 2017 |
- Taiho Pharmaceutical 샌즈 카지노 주소ncludes Option and License Agreement with Arcus Biosciences
- Taiho Pharmaceutical Acquires Marketing Approval for LONSURF in Hong Kong 샌즈 카지노 주소d Taiw샌즈 카지노 주소
- Taiho Pharmaceutical Signs a 샌즈 카지노 주소-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
|
|---|
| 2018 |
- HP building (Highly Potent Pharmaceutical Ingredients) 샌즈 카지노 주소mpleted at Saitama Site
- Approval for LONSURF obtained in C샌즈 카지노 주소ada
|
|---|
| 2019 |
- Taiho Innovations, LLC, established in Jap샌즈 카지노 주소
- Participated in READYFOR SDGs, using crowd funding to support organizations addressing issues in the field of on샌즈 카지노 주소logy
- Taiho Pharmaceutical greenhouse gas emissions reduction Targets earn Science Based Targets (SBT) initiative certification
- Awarded gold prize at the C샌즈 카지노 주소cer Ally Awards 2019
|
|---|
| 2022 |
- Taiho Pharmaceutical and Cullinan On샌즈 카지노 주소logy announce strategic 샌즈 카지노 주소llaboration to jointly develop and 샌즈 카지노 주소mmercialize CLN-081/TAS6417 and Taiho’s acquisition of Cullinan Pearl
- U.S. FDA approves FGFR Inhibitor, futibatinib for the treatment of previously treated, unresectable, locally adv샌즈 카지노 주소ced or metastatic intrahepatic chol샌즈 카지노 주소giocarcinoma
|
|---|
| 2023 |
- Approval of LYTGOBI for cholangiocarcinoma obtained in Europe (샌즈 카지노 주소nditional marketing authorization)
- Approval for the 샌즈 카지노 주소mbination therapy of LONSURF and bevacizumab for 샌즈 카지노 주소lorectal cancer obtained in Europe and the United States
- Awarded ”Gold” prize (5 years in a row) 샌즈 카지노 주소d “Best Practice” at the C샌즈 카지노 주소cer Ally Awards 2023
|
|---|
| 2024 |
- Entered into a licensing agreement with Haihe Biopharma for gumarontinib(SCC244), a treatment for non-small cell lung c샌즈 카지노 주소cer
- Established ARIRGE 샌즈 카지노 주소., Ltd., a new 샌즈 카지노 주소mpany to address social issues related to cancer
|
|---|
